NEW YORK, Nov. 23 (GenomeWeb News) - Shares in DeCode Genetics were up 5.20 percent at $6.47 in mid-afternoon trading after the company announced plans to jointly develop and market cardiovascular and cerebrovascular drugs with Roche.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
